论文部分内容阅读
目的探讨前列安栓结合西地那非治疗慢性非细菌性前列腺炎(CNP)合并勃起功能障碍(ED)的临床效果。方法CNP合并ED患者69例,随机分为两组,治疗组35例,使用前列安栓4周后加用西地那非治疗。对照组34例持续使用前列安栓8周。分别于4~8周末进行NIH-CPSI评分和IIEF-5评分观察疗效。结果4周末治疗组和对照组NIH-CPSI分别为(13.1±4.7),(13.3±4.5),较治疗前均显著下降(P<0.01)两组间比较差异无统计学意义(P>0.05),两组IIEF-5评分分别为(14.1±3.3)、(14.3±5.0)较治疗前有所上升(P<0.01),但两组间比较差异无统计学意义(P>0.05),8周后治疗组NIH-CPSI评分(7.8±2.8)、IIEF-5评分(20.1±4.4)与4周末比较差异均有统计学意义(P<0.01);对照组NIH-CPSI评分(12.7±2.3)、IIEF-5评分(14.3±4.5)、与4周末比较差异均无统计学意义(P>0.05);两组间NIH-CPSI与IIEF-5评分比较差异均有统计学意义(P<0.01),治疗组IIEF-5评分值与NIH-CPSI值呈负相关关系。结论对CNP合并ED患者在使用前列安栓加用西地那非能有效治疗ED,同时使NIH-CPSI评分降低,促进CNP恢复。
Objective To investigate the clinical efficacy of Qianliean combined with sildenafil in the treatment of chronic non-bacterial prostatitis (CNP) with erectile dysfunction (ED). Methods 69 patients with CN complicated with ED were randomly divided into two groups. The treatment group was 35 cases. The Qianliean suppository was treated with sildenafil for 4 weeks. Control group, 34 cases of continuous use of prostaglandin suppositories for 8 weeks. NIH-CPSI score and IIEF-5 score were observed at 4 to 8 weeks respectively. Results The NIH-CPSI scores of the treatment group and the control group were (13.1 ± 4.7) and (13.3 ± 4.5) at 4weeks respectively, which were significantly lower than those before treatment (P <0.01). There was no significant difference between the two groups (P> 0.05) (14.1 ± 3.3) and (14.3 ± 5.0), respectively, before treatment (P <0.01), but there was no significant difference between the two groups (P> 0.05) The NIH-CPSI score (7.8 ± 2.8) and IIEF-5 score (20.1 ± 4.4) in the post-treatment group were significantly lower than those in the 4-week post treatment group (P <0.01) (P> 0.05). There was significant difference between the two groups in the NIH-CPSI and IIEF-5 scores (P <0.01). There was no significant difference between the two groups in the score of IIEF-5 (14.3 ± 4.5) The treatment group IIEF-5 score and NIH-CPSI value was negatively correlated. Conclusions In patients with CNP complicated with ED, Qianliean suppository plus sildenafil can effectively treat ED while reducing NIH-CPSI score and promoting CNP recovery.